Allogene Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Good morning. I'm Salveen Richter, biotechnology analyst at Goldman Sachs. We're pleased to have Allogene with us here this morning. And with us, we have David Chang, President and CEO.
Questions & Answers
David, you recently presented initial data from the Phase I ALLO-501 study, your allogeneic CAR T at ASCO this year. Could you start by briefly recapping these findings and help put into context for us, how we should think about these results compared to the early autologous CAR T data?
Yes, Salveen, it's a pleasure to be invited to this conference. And too bad that we have to hold this as a virtual conference. I mean, I always love to go down to the Goldman Sachs conference at a wonderful time in June in Southern California, but such is the life nowadays. So we have
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |